EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023.04.14

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023.04.11

Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready

2023.03.08

Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration

2023.02.22

Date

Title

2022-03-22

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

2021-12-20

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-11-10

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-10-27

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021-08-12

Essex Bio-Technology Reports First Half 2021 Financial Results

2021-07-25

Essex Bio-Technology Listed on Two Authoritative Lists

2021-07-19

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-04-30

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT